CY1122181T1 - Φαρμακοτεχνικη μορφη αντισωματος - Google Patents
Φαρμακοτεχνικη μορφη αντισωματοςInfo
- Publication number
- CY1122181T1 CY1122181T1 CY20191101096T CY191101096T CY1122181T1 CY 1122181 T1 CY1122181 T1 CY 1122181T1 CY 20191101096 T CY20191101096 T CY 20191101096T CY 191101096 T CY191101096 T CY 191101096T CY 1122181 T1 CY1122181 T1 CY 1122181T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- pharmaceutical form
- sugars
- formulated
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658472P | 2012-06-12 | 2012-06-12 | |
| PCT/IB2013/054777 WO2013186700A1 (en) | 2012-06-12 | 2013-06-11 | Antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122181T1 true CY1122181T1 (el) | 2020-11-25 |
Family
ID=48914378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101096T CY1122181T1 (el) | 2012-06-12 | 2019-10-22 | Φαρμακοτεχνικη μορφη αντισωματος |
Country Status (37)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| KR102011156B1 (ko) | 2011-01-06 | 2019-08-16 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| LT3060229T (lt) | 2013-10-24 | 2021-09-27 | Astrazeneca Ab | Stabilios vandeninės antikūno vaistinės formos |
| CN104730237A (zh) * | 2013-12-23 | 2015-06-24 | 国家纳米科学中心 | 试纸及其应用以及检测甲胎蛋白抗原、乙肝表面抗原或HIV的gp41抗体的方法 |
| ES3065185T3 (en) | 2014-01-21 | 2026-05-04 | Takeda Pharmaceuticals Co | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| IL247942B (en) | 2014-03-27 | 2022-09-01 | Dyax Corp | Compositions and methods for drops in macular edema as a result of diabetes |
| KR101597037B1 (ko) | 2014-06-26 | 2016-02-24 | 엘지디스플레이 주식회사 | 구동소자의 전기적 특성 편차를 보상할 수 있는 유기발광 표시장치 |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CA3290174A1 (en) * | 2015-03-30 | 2026-03-02 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| DK3386541T3 (da) * | 2015-12-07 | 2020-09-28 | Merck Patent Gmbh | Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab |
| US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| US10994011B2 (en) | 2015-12-18 | 2021-05-04 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human TSLP receptor antibody |
| EA201892735A1 (ru) * | 2016-06-16 | 2019-05-31 | Янссен Вэксинс Энд Превеншн Б.В. | Состав вакцины против hiv |
| DK3529269T3 (da) | 2016-10-19 | 2026-02-23 | Invenra Inc | Antistof-konstruktioner |
| WO2018115485A1 (en) | 2016-12-22 | 2018-06-28 | Pierfrancesco Tassone | A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43 |
| JP2020509025A (ja) * | 2017-03-01 | 2020-03-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | モノクローナル抗体製剤 |
| TW201834639A (zh) * | 2017-03-06 | 2018-10-01 | 德商馬克專利公司 | 水性抗體調配物 |
| BR112019021723A2 (pt) * | 2017-04-18 | 2021-06-29 | Dr. Reddy's Laboratories Limited | formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| ES2965486T3 (es) * | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| MD3672631T3 (ro) * | 2017-08-22 | 2023-09-30 | Biogen Ma Inc | Compoziții farmaceutice conținând anticorpi anti-beta amiloidici |
| KR102581734B1 (ko) | 2017-10-06 | 2023-09-22 | 네오토프 뉴로사이언스 리미티드 | 트랜스타이레틴의 검출 방법 |
| MA51223A (fr) * | 2017-11-29 | 2020-10-07 | Prothena Biosciences Ltd | Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine |
| CN113227127A (zh) | 2018-06-05 | 2021-08-06 | 伦敦大学国王学院 | 向胃肠系统递送酬载的btnl3/8导引构建体 |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| CN113194993A (zh) | 2018-12-18 | 2021-07-30 | 诺华股份有限公司 | 含高浓度抗vegf抗体的蛋白质溶液配制品 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| JP2022521624A (ja) * | 2019-02-26 | 2022-04-11 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 抗ｃｄ４７抗体を含む製剤、その調製方法および使用 |
| CA3160207A1 (en) | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
| CN113116812A (zh) * | 2019-12-30 | 2021-07-16 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| CN115052622B (zh) * | 2020-01-21 | 2026-03-06 | 夏尔巴生物技术(杭州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
| CN116194478A (zh) | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
| JP7834711B2 (ja) * | 2020-08-04 | 2026-03-24 | ノバルティス アーゲー | Ｂ細胞悪性腫瘍の治療 |
| IL300087A (en) * | 2020-08-04 | 2023-03-01 | Novartis Ag | Treatment of CLL |
| JP2023553641A (ja) * | 2020-12-17 | 2023-12-25 | アストラゼネカ アクチボラグ | 抗ｉｌ５ｒ抗体製剤 |
| CN115073598B (zh) * | 2021-03-15 | 2024-02-20 | 盛禾(中国)生物制药有限公司 | 一种抗baffr抗体及其应用 |
| US20240228644A1 (en) * | 2021-05-04 | 2024-07-11 | Novartis Ag | Treatment for systemic lupus erythematosus using anti-baffr antibodies |
| US20240239911A1 (en) | 2021-05-04 | 2024-07-18 | Novartis Ag | Treatment for lupus nephritis using anti-baffr antibodies |
| JP2024537772A (ja) * | 2021-09-29 | 2024-10-16 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｂａｆｆ－ｒを標的化する抗体及びその使用 |
| EP4615502A1 (en) | 2022-11-07 | 2025-09-17 | Upstream Bio, Inc. | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
| CN118681009A (zh) * | 2023-03-21 | 2024-09-24 | 百奥泰生物制药股份有限公司 | 一种复方制剂及其应用 |
| CN116712390B (zh) * | 2023-08-04 | 2023-11-14 | 上海览屹医药科技有限公司 | 一种高浓度高稳定性的抗体制剂及其制备方法 |
| WO2025257781A1 (en) * | 2024-06-14 | 2025-12-18 | Novartis Ag | Treatment of systemic sclerosis using anti-baff-r antibodies |
| WO2025263459A1 (ja) * | 2024-06-17 | 2025-12-26 | 学校法人神戸薬科大学 | バイオ医薬品組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2000078930A1 (en) | 1999-06-23 | 2000-12-28 | Oregon Health Sciences University | Method for enhancing hematopoiesis |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| EP3210624A1 (en) | 2002-02-27 | 2017-08-30 | Immunex Corporation | Stabilized tnfr-fc composition comprising arginine |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0518994A2 (pt) * | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| AU2009272771B2 (en) * | 2008-07-17 | 2012-09-20 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| RU2558821C2 (ru) * | 2009-11-17 | 2015-08-10 | Ипсен Фарма С.А.С. | ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1 |
| WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
-
2013
- 2013-06-07 US US13/912,355 patent/US9216219B2/en active Active
- 2013-06-10 MA MA37616A patent/MA37616A1/fr unknown
- 2013-06-11 AU AU2013276112A patent/AU2013276112B2/en active Active
- 2013-06-11 JP JP2015516723A patent/JP6265978B2/ja active Active
- 2013-06-11 FI FIEP19185836.4T patent/FI3593814T3/fi active
- 2013-06-11 EA EA201492292A patent/EA033373B1/ru not_active IP Right Cessation
- 2013-06-11 SG SG11201408174UA patent/SG11201408174UA/en unknown
- 2013-06-11 LT LTEP19185836.4T patent/LT3593814T/lt unknown
- 2013-06-11 EP EP13744818.9A patent/EP2858671B1/en active Active
- 2013-06-11 MY MYPI2014703690A patent/MY179818A/en unknown
- 2013-06-11 HU HUE13744818A patent/HUE045523T2/hu unknown
- 2013-06-11 WO PCT/IB2013/054777 patent/WO2013186700A1/en not_active Ceased
- 2013-06-11 MX MX2014015262A patent/MX363380B/es unknown
- 2013-06-11 KR KR1020157000336A patent/KR102124820B1/ko active Active
- 2013-06-11 ES ES13744818T patent/ES2751659T3/es active Active
- 2013-06-11 DK DK13744818.9T patent/DK2858671T3/da active
- 2013-06-11 PT PT191858364T patent/PT3593814T/pt unknown
- 2013-06-11 PE PE2014002437A patent/PE20150200A1/es not_active Application Discontinuation
- 2013-06-11 PT PT137448189T patent/PT2858671T/pt unknown
- 2013-06-11 DK DK19185836.4T patent/DK3593814T3/da active
- 2013-06-11 PL PL13744818T patent/PL2858671T3/pl unknown
- 2013-06-11 TW TW102120795A patent/TWI653983B/zh active
- 2013-06-11 BR BR112014030820-9A patent/BR112014030820B1/pt active IP Right Grant
- 2013-06-11 CA CA2875386A patent/CA2875386C/en active Active
- 2013-06-11 NZ NZ630885A patent/NZ630885A/en not_active IP Right Cessation
- 2013-06-11 PL PL19185836.4T patent/PL3593814T3/pl unknown
- 2013-06-11 SI SI201331596T patent/SI2858671T1/sl unknown
- 2013-06-11 LT LT13744818T patent/LT2858671T/lt unknown
- 2013-06-11 HR HRP20260513TT patent/HRP20260513T1/hr unknown
- 2013-06-11 EP EP19185836.4A patent/EP3593814B1/en active Active
- 2013-06-11 CN CN201380031181.8A patent/CN104363920B/zh active Active
- 2013-06-11 SI SI201332122T patent/SI3593814T1/sl unknown
- 2013-06-11 EP EP26152709.7A patent/EP4725556A3/en active Pending
- 2013-06-11 RS RS20260421A patent/RS67957B1/sr unknown
- 2013-06-11 HR HRP20191827TT patent/HRP20191827T1/hr unknown
- 2013-06-11 ES ES19185836T patent/ES3067493T3/es active Active
- 2013-06-12 AR ARP130102057 patent/AR091413A1/es not_active Application Discontinuation
-
2014
- 2014-11-20 ZA ZA2014/08547A patent/ZA201408547B/en unknown
- 2014-11-21 TN TN2014000488A patent/TN2014000488A1/fr unknown
- 2014-11-27 IL IL235966A patent/IL235966B/en active IP Right Grant
- 2014-12-11 PH PH12014502778A patent/PH12014502778A1/en unknown
- 2014-12-11 GT GT201400285A patent/GT201400285A/es unknown
- 2014-12-11 CL CL2014003370A patent/CL2014003370A1/es unknown
- 2014-12-18 CO CO14278419A patent/CO7151487A2/es unknown
-
2015
- 2015-01-12 EC ECIEPI201517314A patent/ECSP15017314A/es unknown
- 2015-11-16 US US14/942,388 patent/US9751951B2/en active Active
-
2017
- 2017-08-31 US US15/692,490 patent/US20180051092A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/980,411 patent/US10689451B2/en active Active
-
2019
- 2019-10-22 CY CY20191101096T patent/CY1122181T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502778B1 (en) | Antibody formulation | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| CO2017004596A2 (es) | Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| TN2014000431A1 (en) | Antibody formulatoin | |
| CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| WO2012076670A3 (en) | Antibody formulation | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| MX2016015006A (es) | Formulacion de anticuerpos. | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición | |
| MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
| CO2017007316A2 (es) | Formulación farmacéutica | |
| EA201590752A1 (ru) | Препараты производных пиримидиндиона | |
| CY1122598T1 (el) | Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης | |
| AR130115A2 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| TR201203086A2 (tr) | Sefiksim ve klavulanik asit içeren farmasötik dozaj formu. |